The biotechnology sector offers investors a high-risk, high-reward opportunity as companies race to bring breakthrough ...

I continue to rate Ligand Pharmaceuticals stock as a "Buy" citing strong liquidity and a clean balance sheet. Its Q3 2024 earnings report beat on the top and bottom lines raising prior guidance, ...

As of Tuesday, January 13, Ligand Pharmaceuticals Incorporated’s LGND share price has dipped by 7.83%, which has investors ...

SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) (“Ligand,” the “Company” or “we”) announced that it has entered into a merger agreement, pursuant to which its subsidiary ...

JUPITER, Fla.--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) will host its Investor and Analyst Day in Boston today. The event will feature presentations from Ligand CEO Todd ...

Aligos Therapeutics Inc. has identified programmed cell death 1 (PDCD1; PD-1; CD279)/PD-1 ligand 1 (PD-L1; CD274) interaction inhibitors reported to be useful for the treatment of liver cancer ...

GPCRs (G-protein-coupled receptors) represent the largest family of membrane receptors currently targeted by approved drugs. It is estimated that approximately 700 approved drugs target GPCRs ...

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family ...

A new study published in the Journal of the National Cancer Institute brings researchers and oncologists one step closer to better understanding the complexities of PD-1 inhibitors, a common type of ...